Daiichi and AstraZeneca’s Enhertu highlights PFS benefits in breast cancer trial

Enhertu (trastuzumab deruxtecan) with pertuzumab, developed by Daiichi Sankyo and AstraZeneca, has shown positive results in the Phase III DESTINY-Breast09 trial for HER2-positive metastatic breast cancer. The trial demonstrated a significant improvement in progression-free survival (PFS) when the combination was used as a first-line treatment, compared to taxane, trastuzumab, and pertuzumab (THP).

The trial, which enrolled 1,157 participants globally, showed that all pre-specified subgroups experienced PFS benefits with the Enhertu combination. Although overall survival (OS) data is still immature, there is an early trend in favor of the combination. The secondary endpoints included pharmacokinetics, objective response rate, and safety, with Enhertu’s safety profile aligning with known profiles of the individual therapies.

Enhertu, a HER2-directed ADC, has now been approved in over 75 countries for HER2-positive breast cancer and is a key product in both companies’ oncology portfolios.

26-04-2025